ATC Group: A07EC03 Olsalazine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07EC03 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Antidiarrheals, intestinal antiinflammatory/antiinfective agents
3
Intestinal antiinflammatory agents
4
Aminosalicylic acid and similar agents
5
A07EC03
Olsalazine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
1 g

Active ingredients in A07EC03

Active Ingredient
Description

Olsalazine is bioconverted to 5-aminosalicylic acid (5-ASA), which has anti-inflammatory activity in ulcerative colitis. The conversion of olsalazine to mesalamine (5-ASA) in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic.

Related product monographs

Title
Type
Country
Structured Product Labeling (SPL)
US

Medicines in this ATC group

United States (US)

Australia (AU)

Canada (CA)

Finland (FI)

France (FR)

Ireland (IE)

Netherlands (NL)

New Zealand (NZ)

South Africa (ZA)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.